To determine if immunoregulatory T-cell inhibition by Ontak followed by the administration of an autologous tumor lysate-loaded dendritic cell vaccine enhances the immune response in patients with relapsed/refractory ovarian cancer

To define the in vitro and in vivo responses of Ontak with and without DC vaccination.

To characterize the toxicities of this novel Treg/DC-based vaccination strategy.

Maximum tolerated dose (MTD) of Anetumab ravtansine in combination with pegylated liposomal doxorubicin (at 30 mg/m2 of body surface area) when given every three weeks

Incidence of serious and non-serious adverse events (AEs)

AUC (area under the plasma concentration vs. time curve from zero to infinity after single (first) dose) of Anetumab ravtansine analytes (Antibody drug conjugates, Total Antibody, metabolites DM4, and DM4-Me)

(and 8 more...)

61

Female

18 Years and older (Adult, Senior)

NCT02751918

18326

June 8, 2016

August 17, 2019

September 14, 2019

April 26, 2016

January 24, 2018

Yale University School of MedicineNew Haven, Connecticut, United States

Oklahoma University Health Science CenterOklahoma City, Oklahoma, United States